World’s First RSV Vaccine gets approval in the USA
For the first time, a respiratory syncytial virus (RSV) vaccination appears ready to aid thousands of people. It’s been decades in the making, but on May 3 the US Food and Drug Administration (FDA) approved the vaccine for use in adults over the age of 60. Availability of the Vaccine The vaccine would be accessible at US pharmacies and clinics by the fall if it were to be approved by the US Centres for Disease Control and Prevention, which might happen by June. Respiratory Syncytial Virus often doesn’t cause much more harm than a cold, but it can be fatal for elderly people, especially those with underlying medical issues. RSV kills over 14,000 seniors over the age of 65 annually in the US alone, and tens of thousands more are hospitalized. If the virus spreads, young children are also at risk. In the US, severe infections are thought to be the cause of 100 to 500 baby fatalities annually; however, the number is significantly greater in underdeveloped nations. USFDA approves the world...